151. Treatment strategy for BVO-ME based on long-term outcomes correlating retinal structure by OCT image and visual acuity
- Author
-
Yuki Hattori, Ryo Fujiwara, Hidetsugu Mori, Motoki Kimura, Haruhiko Yamada, and Kanji Takahashi
- Subjects
Intravitreal anti-VEGF treatment ,BRVO ,CME ,EZ ,Foveal bulge ,SRD ,Ophthalmology ,RE1-994 - Abstract
Abstract Background Intravitreal anti-vascular endothelial growth factor (VEGF) is a mainstream treatment for reducing ME secondary to BRVO (BVO-ME). Regrettably, most reports of intravitreal anti-VEGF for BVO-ME have disclosed only short-term outcomes. Here, we characterized long-term indicators for the visual prognosis of patients with BVO-ME, including the correlation between retinal structure by OCT and visual acuity. Methods Patients with BVO-ME were retrospectively recruited based on clinical records in Kansai Medical University Hospital from June 2012 to March 2022. This study enrolled patients with vision loss who received intravitreal injection of anti-VEGF for BVO-ME. Inclusion criteria were that patients received intravitreal injection of anti-VEGF as their first treatment and were followed for at least 36 months. Exclusion criteria were those patients with ocular disease other than BRVO or who had been previously treated for BVO-ME. Patients were divided into two groups according to BCVA at the final visit: Group A (≥ 0.7) and Group B (
- Published
- 2023
- Full Text
- View/download PDF